Ha yeah nah. Cash burn will drop like a stone. Expenses are expected to be reasonably flat will renue increases. The audacious raise was pre covid. Great timing and luck
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
